{
    "root": "5ed11ef9-73c0-42d1-9cac-0fba10a1f991",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Cyclophosphamide",
    "value": "20250122",
    "ingredients": [
        {
            "name": "Cyclophosphamide",
            "code": "8N3DW7272P",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_4027"
        },
        {
            "name": "Mannitol",
            "code": "3OWL53L36A",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_29864"
        },
        {
            "name": "Water",
            "code": "059QF0KO0R",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_15377"
        }
    ],
    "indications": {
        "text": "cyclophosphamide injection alkylating indicated treatment adults pediatric patients : malignant diseases : malignant lymphomas : hodgkin 's disease , lymphocytic lymphoma , mixed-cell type lymphoma , histiocytic lymphoma , burkitt 's lymphoma ; multiple myeloma , leukemias , mycosis fungoides , neuroblastoma , adenocarcinoma ovary , retinoblastoma , breast carcinoma ( 1.1 ) minimal change nephrotic syndrome pediatric patients : biopsy proven minimal change nephrotic syndrome patients failed adequately respond unable tolerate adrenocorticosteroid therapy ( 1.2 ) limitations : safety effectiveness treatment nephrotic syndrome adults renal disease established . ( 1.2 )",
        "doid_entities": [
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            },
            {
                "text": "lymphoma (DOID:0060058)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0060058"
            },
            {
                "text": "histiocytic lymphoma (DOID:8538)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_8538"
            },
            {
                "text": "multiple myeloma (DOID:9538)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_9538"
            },
            {
                "text": "mycosis (DOID:1564)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1564"
            },
            {
                "text": "mycosis fungoides (DOID:8691)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_8691"
            },
            {
                "text": "neuroblastoma (DOID:769)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_769"
            },
            {
                "text": "adenocarcinoma (DOID:299)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_299"
            },
            {
                "text": "retinoblastoma (DOID:768)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_768"
            },
            {
                "text": "breast carcinoma (DOID:3459)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_3459"
            },
            {
                "text": "carcinoma (DOID:305)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_305"
            },
            {
                "text": "nephrotic syndrome (DOID:1184)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1184"
            },
            {
                "text": "syndrome (DOID:225)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_225"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "immediately cyclophosphamide injection , administer adequate amounts fluid reduce risk urinary tract toxicity ( 2.1 ) . malignant diseases : adult pediatric patients ( 2.2 ) intravenous : initial course patients hematologic deficiency : 40 mg per kg 50 mg per kg divided doses 2 5 days . regimens include 10 mg per kg 15 mg per kg given every 7 10 days 3 mg per kg 5 mg per kg twice weekly . oral : 1 mg per kg per day 5 mg per kg per day initial maintenance dosing . minimal change nephrotic syndrome pediatric patients ( 2.3 ) oral : 2 mg per kg daily 8 12 weeks ( maximum cumulative dose 168 mg per kg ) . treatment beyond 90 days increases probability sterility males . ( 8.4 )",
        "doid_entities": [
            {
                "text": "nephrotic syndrome (DOID:1184)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1184"
            },
            {
                "text": "syndrome (DOID:225)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_225"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "cyclophosphamide injection , usp supplied follows : ndc cyclophosphamide injection , usp package factor 25021-247-50 500 mg single-dose vial 1 vial per carton 25021-248-51 1 gram single-dose vial 1 vial per carton 25021-249-51 2 grams single-dose vial 1 vial per carton cyclophosphamide injection , usp sterile white cake containing cyclophosphamide mannitol .",
    "adverseReactions": "hypersensitivity cyclophosphamide ( 4 ) urinary outflow obstruction ( 4 )",
    "indications_original": "Cyclophosphamide for Injection is an alkylating drug indicated for treatment of adults and pediatric patients with: Malignant Diseases : malignant lymphomas: Hodgkin's disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt's lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of ovary, retinoblastoma, breast carcinoma ( 1.1 ) Minimal Change Nephrotic Syndrome in Pediatric Patients : biopsy proven minimal change nephrotic syndrome patients who failed to adequately respond to or are unable to tolerate adrenocorticosteroid therapy ( 1.2 ) Limitations of Use: The safety and effectiveness for the treatment of nephrotic syndrome in adults or other renal disease has not been established. ( 1.2 )",
    "contraindications_original": "During or immediately after Cyclophosphamide for Injection administration, administer adequate amounts of fluid to reduce the risk of urinary tract toxicity ( 2.1 ). Malignant Diseases: Adult and Pediatric Patients ( 2.2 ) Intravenous: Initial course for patients with no hematologic deficiency:  40 mg per kg to 50 mg per kg in divided doses over 2 to 5 days. Other regimens include 10 mg per kg to 15 mg per kg given every 7 to 10 days or 3 mg per kg to 5 mg per kg twice weekly. Oral: 1 mg per kg per day to 5 mg per kg per day for both initial and maintenance dosing. Minimal Change Nephrotic Syndrome in Pediatric Patients ( 2.3 ) Oral: 2 mg per kg daily for 8 to 12 weeks (maximum cumulative dose 168 mg per kg). Treatment beyond 90 days increases the probability of sterility in males. ( 8.4 )",
    "warningsAndPrecautions_original": "Cyclophosphamide for Injection, USP is supplied as follows:\n\n                  \n                     \n                     \n                     \n                     \n                        \n                           \n                              NDC\n                           \n                           \n                              Cyclophosphamide for Injection, USP\n                           \n                           \n                              Package Factor\n                           \n                        \n                        \n                           25021-247-50\n\n                           500 mg Single-Dose Vial\n\n                           1 vial per carton\n\n                        \n                        \n                           25021-248-51\n\n                           1 gram Single-Dose Vial\n\n                           1 vial per carton\n\n                        \n                        \n                           25021-249-51\n\n                           2 grams Single-Dose Vial\n\n                           1 vial per carton\n\n                        \n                     \n                  \n                  Cyclophosphamide for Injection, USP is a sterile white cake containing cyclophosphamide and mannitol.",
    "adverseReactions_original": "Hypersensitivity to cyclophosphamide ( 4 ) Urinary outflow obstruction ( 4 )",
    "drug": [
        {
            "name": "Cyclophosphamide",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_4027"
        }
    ]
}